Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy SCYNEXIS stock | $5.18

Learn how to easily invest in SCYNEXIS stock.

SCYNEXIS Inc is a drug manufacturers-specialty & generic business based in the US. SCYNEXIS shares (SCYX) are listed on the NASDAQ and all prices are listed in US Dollars. SCYNEXIS employs 38 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in SCYNEXIS

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SCYX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.


Use our graph to track the performance of SCYX stocks over time.

SCYNEXIS shares at a glance

Information last updated 2021-10-16.
Latest market close$5.18
52-week range$4.25 - $10.25
50-day moving average $5.82
200-day moving average $7.07
Wall St. target price$24.36
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.86

Buy SCYNEXIS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy SCYNEXIS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SCYNEXIS price performance over time

Historical closes compared with the close of $5.18 from 2021-10-22

1 week (2021-10-15) -7.00%
1 month (2021-09-23) -7.50%
3 months (2021-07-23) -26.63%
6 months (2021-04-23) -29.23%
1 year (2020-10-23) 2.17%
2 years (2019-10-23) 366.67%
3 years (2018-10-23) 449.89%
5 years (2016-10-21) 41.92%

SCYNEXIS financials

Revenue TTM $12.1 million
Gross profit TTM $121,000
Return on assets TTM -34.52%
Return on equity TTM -231.91%
Profit margin 0%
Book value $1.40
Market capitalisation $129.3 million

TTM: trailing 12 months

Shorting SCYNEXIS shares

There are currently 3.5 million SCYNEXIS shares held short by investors – that's known as SCYNEXIS's "short interest". This figure is 2.5% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting SCYNEXIS shares can be evaluated.

SCYNEXIS's "short interest ratio" (SIR)

SCYNEXIS's "short interest ratio" (SIR) is the quantity of SCYNEXIS shares currently shorted divided by the average quantity of SCYNEXIS shares traded daily (recently around 153794.39579685). SCYNEXIS's SIR currently stands at 22.84. In other words for every 100,000 SCYNEXIS shares traded daily on the market, roughly 22840 shares are currently held short.

However SCYNEXIS's short interest can also be evaluated against the total number of SCYNEXIS shares, or, against the total number of tradable SCYNEXIS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SCYNEXIS's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 SCYNEXIS shares in existence, roughly 150 shares are currently held short) or 0.1951% of the tradable shares (for every 100,000 tradable SCYNEXIS shares, roughly 195 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against SCYNEXIS.

Find out more about how you can short SCYNEXIS stock.

SCYNEXIS share dividends

We're not expecting SCYNEXIS to pay a dividend over the next 12 months.

Have SCYNEXIS's shares ever split?

SCYNEXIS's shares were split on a 1:10 basis on 16 July 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SCYNEXIS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for SCYNEXIS shares which in turn could have impacted SCYNEXIS's share price.

SCYNEXIS share price volatility

Over the last 12 months, SCYNEXIS's shares have ranged in value from as little as $4.25 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

SCYX.US volatility(beta: 2.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SCYNEXIS's is 2.2317. This would suggest that SCYNEXIS's shares are significantly more volatile than the average for this exchange and represent a higher risk.

SCYNEXIS overview

SCYNEXIS, Inc. , a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. , Hansoh (Shanghai) Health Technology Co. , Ltd.

Frequently asked questions

What percentage of SCYNEXIS is owned by insiders or institutions?
Currently 0.844% of SCYNEXIS shares are held by insiders and 50.126% by institutions.
How many people work for SCYNEXIS?
Latest data suggests 38 work at SCYNEXIS.
When does the fiscal year end for SCYNEXIS?
SCYNEXIS's fiscal year ends in December.
Where is SCYNEXIS based?
SCYNEXIS's address is: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
What is SCYNEXIS's ISIN number?
SCYNEXIS's international securities identification number is: US8112922005
What is SCYNEXIS's CUSIP number?
SCYNEXIS's Committee on Uniform Securities Identification Procedures number is: 811292101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site